MX365713B - Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos. - Google Patents
Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.Info
- Publication number
- MX365713B MX365713B MX2015012341A MX2015012341A MX365713B MX 365713 B MX365713 B MX 365713B MX 2015012341 A MX2015012341 A MX 2015012341A MX 2015012341 A MX2015012341 A MX 2015012341A MX 365713 B MX365713 B MX 365713B
- Authority
- MX
- Mexico
- Prior art keywords
- white blood
- enrichment
- cells
- circulating tumor
- blood cells
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/54333—Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a un método para remover glóbulos bancos de una muestra que comprende células extrañas enrique sidas, enriquecidas por métodos inmunomagnéticos y glóbulos blancos, tal método caracterizado porque comprende (a) tratar una muestra que comprende células extrañas enriquecidas conjugadas a partículas magnéticas de ferrofluido y enriquecidas por métodos inmunomagnéticos y glóbulos blancos con un marcador de leucocito que se conjuga a un hapteno bajo condiciones que etiquetan los glóbulos blancos con el marcador de leucocito conjugado al hapteno, (b) tratar la composición de la etapa (a) con un segundo medio que se adhiere al hapteno de los glóbulos blancos etiquetados, y separar el segundo medio y sus glóbulos blancos etiquetados adheridos de la composición de la etapa (b) la cual contiene células extrañas enriquecidas adicionales, en donde las células tumorales circulantes (CTCs), células endoteliales circulantes (CECs), células de mieloma múltiples circulantes (CMMCs), y células de melanoma circulantes (CMCs).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787611P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027701 WO2014152758A1 (en) | 2013-03-15 | 2014-03-14 | Enrichment of circulating tumor cells by depleting white blood cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012341A MX2015012341A (es) | 2016-06-06 |
| MX365713B true MX365713B (es) | 2019-06-11 |
Family
ID=50631046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012341A MX365713B (es) | 2013-03-15 | 2014-03-14 | Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9823238B2 (es) |
| EP (1) | EP2972359B1 (es) |
| JP (1) | JP6563379B2 (es) |
| CN (1) | CN105026934A (es) |
| AU (1) | AU2014239168A1 (es) |
| BR (1) | BR112015022962A2 (es) |
| CA (1) | CA2906900A1 (es) |
| CY (1) | CY1123698T1 (es) |
| DK (1) | DK2972359T3 (es) |
| ES (1) | ES2846224T3 (es) |
| HK (2) | HK1216442A1 (es) |
| HR (1) | HRP20201907T1 (es) |
| HU (1) | HUE052519T2 (es) |
| LT (1) | LT2972359T (es) |
| MX (1) | MX365713B (es) |
| PL (1) | PL2972359T3 (es) |
| PT (1) | PT2972359T (es) |
| RS (1) | RS61052B1 (es) |
| SI (1) | SI2972359T1 (es) |
| WO (1) | WO2014152758A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108061804B (zh) * | 2016-11-09 | 2020-05-12 | 北京大学人民医院 | 用于诊断子宫内膜异位症的生物标志物 |
| CN109991410B (zh) * | 2017-12-29 | 2022-07-05 | 上海白泽医学检验所有限公司 | 一种含抗cd45单抗的组合物及其使用方法 |
| CN109439732B (zh) * | 2018-12-25 | 2024-04-12 | 迈迪速能医学技术（天津）有限公司 | 一种用于三维无创肿瘤早筛的试剂盒 |
| US11890616B2 (en) | 2019-03-26 | 2024-02-06 | The Curators Of The University Of Missouri | Microfluidic device for capture of micrometer scale objects and methods of using the device |
| KR102346111B1 (ko) * | 2020-02-07 | 2022-01-03 | 주식회사 싸이토딕스 | Ctc 분리용 마그네틱 비드 및 이를 이용한 ctc 분리방법 |
| IL301032A (en) * | 2020-09-02 | 2023-05-01 | Menarini Silicon Biosystems Spa | System, kit, method and process for sample handling |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE162631T1 (de) | 1989-11-13 | 1998-02-15 | Childrens Medical Center | Ein nichtinvasives verfahren zur trennung und zum nachweis von fetaler dna |
| AU760560B2 (en) | 1998-02-12 | 2003-05-15 | Board Of Regents, The University Of Texas System | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| CA2279476C (en) * | 1998-07-31 | 2011-09-27 | Stemcell Technologies Inc. | Novel antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions |
| US7364921B1 (en) * | 1999-01-06 | 2008-04-29 | University Of Medicine And Dentistry Of New Jersey | Method and apparatus for separating biological materials and other substances |
| WO2001014591A1 (en) * | 1999-08-21 | 2001-03-01 | Fox John S | High sensitivity biomolecule detection with magnetic particles |
| CN1871517A (zh) * | 2002-02-19 | 2006-11-29 | 免疫公司 | 快速有效分离循环癌细胞的方法和试剂 |
| CA2504279A1 (en) * | 2005-04-15 | 2006-10-15 | University Of Saskatchewan | Materials and method of modulating the immune response using t helper-antigen presenting cells |
| US7901950B2 (en) | 2005-08-12 | 2011-03-08 | Veridex, Llc | Method for assessing disease states by profile analysis of isolated circulating endothelial cells |
| US8889361B2 (en) * | 2007-09-19 | 2014-11-18 | The Research Foundation For The State University Of New York | Gene expression signatures in enriched tumor cell samples |
| WO2009070392A1 (en) | 2007-11-27 | 2009-06-04 | Veridex, Llc | Automated enumeration and characterization of circulating melanoma cells in blood |
| US20090191535A1 (en) * | 2007-12-22 | 2009-07-30 | Mark Carle Connelly | Method of assessing metastatic carcinomas from circulating endothelial cells and disseminated tumor cells |
| CN101469310B (zh) | 2007-12-28 | 2014-03-19 | 北京百奥科生物技术有限公司 | 从生物学样品富集靶细胞的方法及除去白细胞的方法 |
| US8569077B2 (en) | 2008-05-19 | 2013-10-29 | Veridex, Llc | Imaging of immunomagnetically enriched rare cells |
| US9034658B2 (en) * | 2009-11-23 | 2015-05-19 | The General Hospital Corporation | Microfluidic devices for the capture of biological sample components |
| EP2595637B1 (en) * | 2010-07-22 | 2017-11-01 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
| MX351113B (es) | 2011-07-21 | 2017-10-02 | Janssen Diagnostics Llc | Ensayo para capturar y detectar células circulantes de mieloma múltiple de la sangre. |
| AU2013235600B2 (en) * | 2012-03-21 | 2017-12-07 | Dana-Farber Cancer Institute, Inc. | Isolation and use of human lymphoid organ-derived suppressive stromal cells |
| US20140011685A1 (en) | 2012-07-03 | 2014-01-09 | Yixin Wang | Genomic diagnostics using circulating endothelial cells |
-
2014
- 2014-03-14 RS RS20201358A patent/RS61052B1/sr unknown
- 2014-03-14 WO PCT/US2014/027701 patent/WO2014152758A1/en active Application Filing
- 2014-03-14 AU AU2014239168A patent/AU2014239168A1/en not_active Abandoned
- 2014-03-14 DK DK14721102.3T patent/DK2972359T3/da active
- 2014-03-14 CN CN201480015641.2A patent/CN105026934A/zh active Pending
- 2014-03-14 EP EP14721102.3A patent/EP2972359B1/en active Active
- 2014-03-14 MX MX2015012341A patent/MX365713B/es active IP Right Grant
- 2014-03-14 US US14/211,630 patent/US9823238B2/en active Active
- 2014-03-14 CA CA2906900A patent/CA2906900A1/en not_active Abandoned
- 2014-03-14 ES ES14721102T patent/ES2846224T3/es active Active
- 2014-03-14 LT LTEP14721102.3T patent/LT2972359T/lt unknown
- 2014-03-14 HU HUE14721102A patent/HUE052519T2/hu unknown
- 2014-03-14 BR BR112015022962A patent/BR112015022962A2/pt not_active IP Right Cessation
- 2014-03-14 PL PL14721102T patent/PL2972359T3/pl unknown
- 2014-03-14 SI SI201431716T patent/SI2972359T1/sl unknown
- 2014-03-14 PT PT147211023T patent/PT2972359T/pt unknown
- 2014-03-14 JP JP2016502523A patent/JP6563379B2/ja active Active
-
2016
- 2016-04-19 HK HK16104443.7A patent/HK1216442A1/zh unknown
- 2016-06-30 HK HK16107632.1A patent/HK1219776A1/zh unknown
-
2017
- 2017-10-11 US US15/729,957 patent/US10365266B2/en active Active
-
2020
- 2020-11-30 HR HRP20201907TT patent/HRP20201907T1/hr unknown
- 2020-12-02 CY CY20201101139T patent/CY1123698T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2846224T3 (es) | 2021-07-28 |
| HUE052519T2 (hu) | 2021-05-28 |
| CN105026934A (zh) | 2015-11-04 |
| US9823238B2 (en) | 2017-11-21 |
| RS61052B1 (sr) | 2020-12-31 |
| US10365266B2 (en) | 2019-07-30 |
| JP6563379B2 (ja) | 2019-08-21 |
| CY1123698T1 (el) | 2022-03-24 |
| DK2972359T3 (da) | 2020-11-09 |
| WO2014152758A1 (en) | 2014-09-25 |
| HK1216442A1 (zh) | 2016-11-11 |
| JP2016519286A (ja) | 2016-06-30 |
| BR112015022962A2 (pt) | 2017-07-18 |
| PL2972359T3 (pl) | 2021-03-08 |
| SI2972359T1 (sl) | 2021-01-29 |
| AU2014239168A1 (en) | 2015-10-29 |
| US20180045712A1 (en) | 2018-02-15 |
| EP2972359A1 (en) | 2016-01-20 |
| EP2972359B1 (en) | 2020-09-23 |
| LT2972359T (lt) | 2020-12-10 |
| PT2972359T (pt) | 2020-10-29 |
| CA2906900A1 (en) | 2014-09-25 |
| HRP20201907T1 (hr) | 2021-01-22 |
| US20140335542A1 (en) | 2014-11-13 |
| HK1219776A1 (zh) | 2017-04-13 |
| MX2015012341A (es) | 2016-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000181A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
| EA202193044A2 (ru) | Способы лечения таупатии | |
| EA202092987A2 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| MX2022000026A (es) | Anticuerpos para tau. | |
| TW201613962A (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| NZ720949A (en) | Methods and compositions for treating aging-associated conditions | |
| PH12015501071A1 (en) | Combination therapy of anti-her3 antibodies | |
| MX2015012401A (es) | Composiciones y metodos de alterar niveles de colesterol. | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| CY1123698T1 (el) | Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων | |
| MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| EA201500943A1 (ru) | Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов | |
| MX2016000997A (es) | Metodos y composiciones para detectar contaminacion bacteriana. | |
| IN2014DN05885A (es) | ||
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
| MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| MX2014014464A (es) | Peptidos penetrantes de celulas y metodos para identificar peptidos penetrantes de celulas. | |
| PH12017501864A1 (en) | Compositions and methods for treating autism | |
| IN2013MU00848A (es) | ||
| MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
| MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
| PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
| MX361773B (es) | Agentes de ligación a tlr3. | |
| EA201590615A1 (ru) | Стимулирующие лактацию композиции на основе фосфатидилсерина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |